Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
Drugs Exp Clin Res
; 13(10): 631-4, 1987.
Article
en En
| MEDLINE
| ID: mdl-3428127
ABSTRACT
The in vitro activities of rifampicin and the new rifamycin FCE 22250 were evaluated against the intracellular pathogens Legionella and Chlamydia trachomatis. The data reported in this study give evidence that FCE 22250 shows excellent in vitro results, even better than those obtained with rifampicin, leading to the possibility of clinical applications of this new drug on Legionnaire's disease and chlamydial infections.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Rifampin
/
Rifamicinas
/
Legionella
/
Chlamydia trachomatis
Idioma:
En
Revista:
Drugs Exp Clin Res
Año:
1987
Tipo del documento:
Article
País de afiliación:
Italia